CN113164551A - 脂联素肽模拟物制剂 - Google Patents

脂联素肽模拟物制剂 Download PDF

Info

Publication number
CN113164551A
CN113164551A CN201980070344.0A CN201980070344A CN113164551A CN 113164551 A CN113164551 A CN 113164551A CN 201980070344 A CN201980070344 A CN 201980070344A CN 113164551 A CN113164551 A CN 113164551A
Authority
CN
China
Prior art keywords
ser
acetic acid
ala
nva
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980070344.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·P·巴曼
K·L·沃德
陈玉岗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allysta Pharmaceuticals Inc
Original Assignee
Allysta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allysta Pharmaceuticals Inc filed Critical Allysta Pharmaceuticals Inc
Publication of CN113164551A publication Critical patent/CN113164551A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201980070344.0A 2018-10-24 2019-10-24 脂联素肽模拟物制剂 Pending CN113164551A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749861P 2018-10-24 2018-10-24
US62/749,861 2018-10-24
PCT/US2019/057876 WO2020086856A1 (en) 2018-10-24 2019-10-24 Adiponectin peptidomimetics formulations

Publications (1)

Publication Number Publication Date
CN113164551A true CN113164551A (zh) 2021-07-23

Family

ID=70326409

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980070344.0A Pending CN113164551A (zh) 2018-10-24 2019-10-24 脂联素肽模拟物制剂

Country Status (11)

Country Link
US (2) US12201668B2 (enExample)
EP (1) EP3870204A4 (enExample)
JP (2) JP7688471B2 (enExample)
KR (1) KR20210118810A (enExample)
CN (1) CN113164551A (enExample)
AU (1) AU2019363588A1 (enExample)
CA (1) CA3116065A1 (enExample)
IL (1) IL282390A (enExample)
SG (1) SG11202103947XA (enExample)
TW (1) TWI921299B (enExample)
WO (1) WO2020086856A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164551A (zh) * 2018-10-24 2021-07-23 雅利斯塔制药公司 脂联素肽模拟物制剂
US20240382564A1 (en) * 2023-04-17 2024-11-21 Allysta Pharmaceuticals, Inc. Methods and Compositions for Treating Muscular Dystrophy and Memory Impairment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106642A (zh) * 2014-09-24 2017-08-29 艾瑞朗医疗公司 拟肽大环化合物及其制剂
CN107530396A (zh) * 2015-05-01 2018-01-02 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333850T3 (de) * 1992-05-06 2011-03-17 Alcon Laboratories, Inc., Fort Worth Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2012142142A2 (en) * 2011-04-12 2012-10-18 Temple University - Of The Commonwealth System Higher Education Adiponectin receptor agonists and methods of use
KR101438744B1 (ko) * 2012-08-02 2014-09-15 전남대학교산학협력단 아디포넥틴을 유효성분으로 포함하는 안구건조증 또는 염증성 안구표면 질환의 예방 또는 치료용 조성물
AU2015317531B2 (en) * 2014-09-17 2020-11-19 Panoptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
CN113164551A (zh) * 2018-10-24 2021-07-23 雅利斯塔制药公司 脂联素肽模拟物制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106642A (zh) * 2014-09-24 2017-08-29 艾瑞朗医疗公司 拟肽大环化合物及其制剂
CN107530396A (zh) * 2015-05-01 2018-01-02 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
暴玉振 等: "《实用急危重症治疗学》", 河南科学技术出版社, pages: 21 - 22 *

Also Published As

Publication number Publication date
AU2019363588A1 (en) 2021-05-13
IL282390A (en) 2021-06-30
TWI921299B (zh) 2026-04-11
US20200129585A1 (en) 2020-04-30
JP7688471B2 (ja) 2025-06-04
EP3870204A1 (en) 2021-09-01
SG11202103947XA (en) 2021-05-28
JP2022505832A (ja) 2022-01-14
KR20210118810A (ko) 2021-10-01
US20250099533A1 (en) 2025-03-27
JP2024178262A (ja) 2024-12-24
WO2020086856A1 (en) 2020-04-30
US12201668B2 (en) 2025-01-21
CA3116065A1 (en) 2020-04-30
TW202033213A (zh) 2020-09-16
EP3870204A4 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
US11464825B2 (en) Adiponectin peptidomimetics for treating ocular disorders
US20250099533A1 (en) Adiponectin peptidomimetics formulations
HK40058825A (en) Adiponectin peptidomimetics formulations
HK40027227A (en) Adiponectin peptidomimetics for treating ocular disorders
JP2020535117A (ja) 眼疾患を治療するためのアディポネクチンペプチド模倣薬
HK1246178B (en) Adiponectin peptidomimetics for treating ocular disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058825

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210723